Paracetamol + Phenylephrine + CPM

Paracetamol + Phenylephrine + CPM Suspension belongs to the Suspensions category and sits at the intersection of Anti-Pyretic, Cough & Cold, and Pediatric Care therapeutic segments — three of the highest-prescription-volume categories in Indian pharmaceutical practice.

The clinical logic of this three-molecule combination is straightforward and powerful for prescribers:

• Paracetamol 250 mg — the gold-standard pediatric antipyretic and analgesic. Reduces fever, headache, and body ache with an excellent safety profile, absence of gastric irritation risk, and clear hepatic toxicity thresholds that enable safe weight-based dosing.
• Phenylephrine HCl 5 mg — a selective alpha-1 adrenergic nasal decongestant. Reduces nasal mucosal edema, relieves blocked nose, and improves nasal airflow — the most physically distressing component of pediatric cold for both children and parents.
• Chlorpheniramine Maleate 1 or 2 mg — a first-generation H1 antihistamine addressing rhinorrhea, sneezing, watery eyes, and postnasal drip. Available in two strengths to match the antihistamine requirement of different prescriber approaches and age groups.

For pharmaceutical marketing companies, this product is a seasonally robust pediatric SKU with repeat prescription cycles driven by the inevitable return of cold-fever seasons. Saar Biotech manufactures it from our manufacturing facility in Baddi with validated three-API suspension quality control, mango and orange flavour development, and a complete range of 60 ml packaging options.

At Saar Biotech, we manufacture Paracetamol + Phenylephrine + CPM Suspension using a controlled oral suspension manufacturing process that ensures dose uniformity, pediatric flavour acceptance, and packaging reliability for the highly competitive 60 ml cold-care segment.

• Dual CPM Strength Flexibility: Saar Biotech supports both CPM 1 mg and CPM 2 mg variants without changing the Paracetamol 250 mg or Phenylephrine 5 mg backbone. This allows B2B partners to launch a two-SKU portfolio targeting different child age groups and symptom severities — giving brands a broader prescriber reach from a single manufacturing relationship.

• Pediatric Taste Masking: Cold suspensions must taste acceptable to children who already feel unwell. We develop mango and orange-flavoured suspension bases that mask the residual bitterness of Chlorpheniramine and the mild harshness of Phenylephrine — ensuring children accept each dose without resistance, which is a genuine commercial differentiator for pediatric cold brands.

• Suspension Uniformity Engineering: Paracetamol is a suspended solid, not dissolved. Poor formulation leads to sedimentation and inconsistent dosing — a critical failure mode for weight-based pediatric antipyretic products. Our suspending agent system ensures rapid, uniform re-dispersion after shaking, so every 5 ml dose delivers a consistent and predictable Paracetamol load.

• 60 ml Pack Premium Execution: From dark amber bottles to drip-off embossed cartons, metallic labels, tricolour measuring cups, and company-logo printed caps — Saar Biotech’s 60 ml packaging options help pediatric cold brands stand out at pharmacy level, where visual differentiation influences both prescriber recommendation and parent preference.

This manufacturing precision ensures your Paracetamol + Phenylephrine + CPM third-party brand delivers reliable fever-and-cold coverage, child-friendly palatability, and shelf-competitive presentation from every manufacturing batch.

Paracetamol + Phenylephrine + CPM Suspension is manufactured and supplied by Saar Biotech for the following established clinical indications in pediatric cold, fever, and upper respiratory symptom management:

• Fever & Body Ache: Paracetamol’s antipyretic action rapidly normalizes elevated body temperature driven by viral cold and flu infections. It simultaneously relieves associated headache, body ache, and general discomfort — making the patient more comfortable while the illness resolves.

• Nasal Congestion: Phenylephrine addresses the nasal blockage that causes the most discomfort in pediatric colds — difficulty breathing through the nose, disturbed sleep, and feeding difficulty in younger children. Its alpha-adrenergic mechanism physically opens blocked nasal passages.

• Runny Nose, Sneezing & Watery Eyes: Chlorpheniramine Maleate blocks the histamine-mediated component of cold symptoms, particularly when the presentation has allergic rhinitis overlap — a very common pattern in Indian children during seasonal transitions.

• Multi-Symptom Cold Management: The combination gives the prescriber a single suspension that addresses four distinct symptom categories simultaneously — fever, pain, congestion, and allergic nasal symptoms — simplifying the prescription and the parent’s medication management burden.

Schedule H — Must be dispensed on a valid medical prescription. Parents should be advised against concurrent use of other paracetamol-containing medicines.

Triple-Component Clinical Mechanism

Paracetamol acts primarily as a centrally-mediated analgesic and antipyretic. While its exact mechanism is structurally distinct from classic NSAIDs (lacking significant peripheral anti-inflammatory action), authoritative pharmacological data indicates it inhibits central cyclooxygenase (COX) pathways — specifically the synthesis of prostaglandins in the hypothalamic thermoregulatory center. This hypothalamic action facilitates vasodilation and sweating to reduce fever. Additional mechanisms, including descending serotonergic pathway modulation, contribute to its effective analgesic properties in pediatric pain management.

Phenylephrine HCl functions as a direct-acting sympathomimetic amine with strong, selective affinity for alpha-1 adrenergic receptors. Oral administration stimulates these receptors on the vascular smooth muscle within the nasal mucosa, inducing rapid vasoconstriction. This targeted reduction in local blood flow significantly decreases the mucosal edema and vascular engorgement responsible for nasal obstruction, restoring pediatric nasal airway patency.

Chlorpheniramine Maleate is a highly effective, first-generation alkylamine antihistamine. It acts as a competitive, reversible antagonist at the histamine H1 receptor. By blocking histamine binding, it prevents the cascade of allergic responses: suppressing capillary permeability (which causes rhinorrhea), reducing glandular hypersecretion, and blocking the sensory nerve stimulation that triggers sneezing and ocular itching. Due to its lipophilic nature, it readily crosses the blood-brain barrier, resulting in mild, predictable sedation.

Manufacturing Integrity

• Three-API Suspension Uniformity: Each of the three active ingredients must be uniformly distributed in the suspension vehicle so that the first and last 5 ml dose drawn from a 60 ml bottle deliver identical active concentrations. Saar Biotech’s high-shear mixing and validated fill procedures ensure this dose-to-dose consistency — which is pharmacologically critical for Paracetamol, where under-dosing reduces antipyretic efficacy and over-dosing creates hepatotoxicity risk.

• pH and Stability Management: The suspension vehicle must remain chemically stable for 24 months under tropical storage conditions (up to 40°C/75% RH). Our formulation team selects preservatives, pH buffers, and suspending agents that protect all three actives from chemical degradation — ensuring the product on the pharmacy shelf after 18 months of distribution retains its full label-declared potency.

• Rapid Fever Reduction: Paracetamol absorption from a well-formulated suspension is rapid — Tmax is typically achieved within 30 to 60 minutes. This fast onset of fever reduction creates a clear, visible clinical outcome that both parents and prescribers notice quickly, building prescription loyalty and brand trust.

• Seasonal Repeat Demand: Pediatric cold and fever suspensions are among the highest-frequency repurchase pharmaceutical products in the Indian market. A well-positioned brand in this category generates consistent prescription cycles through monsoon, winter, and school-infection seasons — giving B2B partners reliable recurring revenue without complex specialty sales force requirements.

• Dual CPM SKU Strategy: Brands that offer both CPM 1 mg and CPM 2 mg variants from the same manufacturing arrangement can capture prescriptions across a wider prescriber base — pediatricians may prefer 1 mg for younger children, while GPs may prefer 2 mg for older children with pronounced allergic cold symptoms.

• 60 ml Price-to-Value Pack: The 60 ml format is ideal for pediatric cold products because it typically covers a 5–7 day treatment course at standard dosing — matching the natural duration of a cold illness. This reduces leftover medicine waste while keeping the per-prescription price accessible across socioeconomic prescriber segments.

Saar Biotech provides Third-Party Manufacturing and Contract Manufacturing for Paracetamol + Phenylephrine + CPM Suspension from our dedicated oral suspension manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Oral liquid and suspension manufacturing area with controlled processing, automated bottle filling, capping, labeling, and carton packing lines suited for 15 ml, 30 ml, and 60 ml pediatric suspension presentations.
• Capacity: Scalable from brand-entry launches to large seasonal batches; 160×60 ml, 200×60 ml, 360×15 ml (with dropper), 200×30 ml distributor dispatch configurations available.
• Quality Lab: In-house GLP-certified lab with validated HPLC assay for all three actives across all four strength variants, plus pH, viscosity, suspension uniformity, MLT, and fill volume checks.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 15 ml, 30 ml, 60 ml PET or dark amber bottles; sticker label, metallic label, silver leafing, drip-off carton, brand embossed carton, sleeve pack, gum label, printed cap, WHO-GMP cap, company-logo PP cap, measuring cup, tricolour measuring cup, dropper (15 ml), with-carton or without-carton supply — across all strength and pack combinations.
• MOQ: Starting at 5,000–10,000 units per SKU; advance seasonal booking recommended for peak cold-fever demand.

1. Warehouse Conditions: Store below 30°C in a cool, dry environment. Do not freeze — sub-zero temperatures will disrupt the suspension matrix and cause irreversible Paracetamol caking at the base of the bottle.
2. Shake Well Before Every Dose: This is the single most important user instruction for a suspension product. Proper shaking ensures the Paracetamol and other suspended components are uniformly redispersed — so every 5 ml dose contains the full declared active content.
3. Measuring Cup Use: A calibrated measuring cup must accompany the 60 ml bottle. Household spoons are unreliable for pediatric weight-based dosing — a 5 ml household spoon can deviate by 1–2 ml, introducing dose inaccuracies in a product where exact Paracetamol dose matters.
4. Light Protection: Dark amber bottles and outer cartons protect the suspension from light-induced degradation. Premium packaging finishes (drip-off, embossed cartons) should be protected from scuffing during transport.

Every commercial batch of Paracetamol + Phenylephrine + CPM Suspension is quarantined until it passes a comprehensive analytical release protocol:

• Three-API HPLC Assay: Simultaneous quantification of Paracetamol 250 mg, Phenylephrine HCl 5 mg, and CPM (1 mg or 2 mg) per 5 ml is executed via High-Performance Liquid Chromatography against Indian Pharmacopoeia (IP) standards, strictly ensuring absolute label claim compliance.
• Suspension Uniformity & Re-Dispersibility: Sediment behavior and post-shaking uniformity are evaluated to ensure dose-to-dose consistency from first to last 5 ml — particularly critical for Paracetamol’s weight-based pediatric dosing requirement.
• pH & Viscosity Testing: The suspension vehicle’s pH and flow characteristics are monitored to maintain stability and correct pourability through a measuring cup.
• Microbial Limit Testing (MLT): Pediatric oral suspensions require strict IP-compliant microbiological testing — confirming the absence of specified pathogens and adherence to total microbial count limits.
• Fill Volume & Pack Inspection: Automated fill-volume checks, cap torque, measuring-cup inclusion, label placement, and carton accuracy are verified before dispatch.
• Certificate of Analysis (COA): Issued with every B2B batch for partner documentation, distributor records, and regulatory files.

• Hepatotoxicity Risk (Paracetamol): The primary critical safety parameter. Severe hepatic necrosis can occur with pediatric overdose due to the accumulation of the toxic metabolite NAPQI when glutathione pathways are overwhelmed. Strict adherence to weight-based dosing (maximum 60 mg/kg/day) is mandatory. Concurrent use of other paracetamol-containing products must be strictly avoided.
• CNS Depression (CPM): Chlorpheniramine produces sedation and somnolence. In rare pediatric cases, paradoxical CNS excitation may occur. Co-administration with other sedatives is contraindicated.
• Sympathomimetic Precautions (Phenylephrine): May cause mild sympathetic stimulation (restlessness, tachycardia). Contraindicated in children with severe hypertension, cardiovascular disease, or those receiving Monoamine Oxidase Inhibitors (MAOIs).
• Regulatory Guidance: Not recommended for children under 2 years of age for symptomatic cough and cold relief without strict, specialized pediatric supervision as per CDSCO guidelines.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Paracetamol + Phenylephrine + CPM Suspension, please use the B2B enquiry form below.